Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSB | P07858 | 3/20 | 0.57 |
| ▸ | CTSK | P43235 | 3/20 | 0.57 |
| ▸ | CTSS | P25774 | 2/20 | 0.57 |
| ▸ | CTSL | P07711 | 2/20 | 0.57 |
| ▸ | CTRB1 | P17538 | 2/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.50 |
| ▸ | CASP1 | P29466 | 2/20 | 0.50 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.49 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9402892 | 1.00 | CTSB (0.57) | CTSBCTSKCTSSCTSLCTRB1 | |
| SCHEMBL5656036 | 0.88 | CASP1 (0.55) | CTSBCTSKCTSSCTSLCTRB1 | |
| SCHEMBL10254007 | 0.86 | CYP1A2 (0.48) | CTSBCTSKCTSSCTSLCTRB1 | |
| SCHEMBL18576284 | 0.85 | CTSB (0.52) | CTSBCTSKCTSSCTSLCTRB1 | |
| SCHEMBL8759866 | 0.84 | CTSB (0.54) | CTSBCTSKCTSSCTSLALDH1A1 | |
| SCHEMBL18576842 | 0.84 | CTSK (0.54) | CTSBCTSKCTSSCTSLCTRB1 | |
| SCHEMBL22225460 | 0.84 | CTSK (0.61) | CTSBCTSKCTSSCTSLALDH1A1 | |
| SCHEMBL28546631 | 0.84 | CTSK (0.67) | CTSBCTSKCTSSCTSLALDH1A1 | |
| SCHEMBL4622697 | 0.84 | CTSK (0.67) | CTSBCTSKCTSSCTSLALDH1A1 | |
| SCHEMBL4800376 | 0.84 | CTSK (0.67) | CTSBCTSKCTSSCTSLALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9650362-B2 | Inhibitors | PROBIODRUG AG (DE) | 2017-05-16 | — | — | US | disclosed |
| US-9650362-B2 | Inhibitors | PROBIODRUG AG (DE) | 2017-05-16 | — | — | US | disclosed |
| US-9173885-B2 | Inhibitors | PROBIODRUG AG (DE) | 2015-11-03 | — | — | US | disclosed |
| EP-2475428-B1 | HETEROCYLCIC DERIVATIVES AS INHIBITORS OF GLUTAMINYL CYCLASE | PROBIODRUG AG (DE) | 2015-07-01 | — | — | EP | disclosed |
| US-8691814-B2 | Deazapurines and uses thereof | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2014-04-08 | — | — | US | disclosed |
| US-20140065095-A1 | NOVEL INHIBITORS | VIVORYON THERAPEUTICS N.V. (DE) | 2014-03-06 | — | — | US | disclosed |
| US-8486940-B2 | Inhibitors | PROBIODRUG AG (DE) | 2013-07-16 | — | — | US | disclosed |
| US-8486940-B2 | Inhibitors | PROBIODRUG AG (DE) | 2013-07-16 | — | — | US | disclosed |
| US-20110105427-A1 | DEAZAPURINES AND USES THEREOF | DAUN JANE | 2011-05-05 | — | — | US | disclosed |
| US-20110092501-A1 | NOVEL INHIBITORS | PROBIODRUG AG (DE) | 2011-04-21 | — | — | US | disclosed |
| US-7868002-B2 | Deazapurines and uses thereof | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2011-01-11 | — | — | US | disclosed |
| EP-1474425-B9 | DEAZAPURINES AND USES THEREOF | EISAI CO LTD (JP) | 2008-07-02 | — | — | EP | disclosed |
| US-20080103137-A1 | Deazapurines and uses thereof | EISAI CO., LTD. | 2008-05-01 | — | — | US | disclosed |
| US-7314936-B2 | Deazapurines and uses thereof | EISAI CO., LTD. (JP) | 2008-01-01 | — | — | US | disclosed |
| EP-1474425-B1 | DEAZAPURINES AND USES THEREOF | EISAI CO LTD (JP) | 2006-05-24 | — | — | EP | disclosed |
| US-20050124649-A1 | Deazapurines and uses thereof | EISAI CO., LTD (JP) | 2005-06-09 | — | — | US | disclosed |
| EP-1474425-A1 | DEAZAPURINES AND USES THEREOF | Eisai Co. Ltd. (JP) | 2004-11-10 | — | — | EP | disclosed |
| US-20040186127-A1 | Novel deazapurines and uses thereof | EISAI CO., LTD. (JP) | 2004-09-23 | — | — | US | disclosed |
| WO-2004063336-A2 | USES OF DEAZAPURINES FOR THE TREATMENT OF REPERFUSION INJURIES, OSTEOPOROSIS AND/OR BONE METASTASIS | EISAI CO. LTD. (JP) | 2004-07-29 | — | — | WO | disclosed |
| WO-2003057696-A1 | DEAZAPURINES AND USES THEREOF | EISAI CO. LTD. (JP) | 2003-07-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110105427-A1 | DEAZAPURINES AND USES THEREOF | TPMT, CD38, CD2 | CTSB 3720/4885CTSK 4501/4885CTSS 4441/4885 |
| US-20050124649-A1 | Deazapurines and uses thereof | TPMT, CD38, CD2 | CTSB 3731/4885CTSK 4516/4885CTSS 4454/4885 |
| US-20110092501-A1 | NOVEL INHIBITORS | GLUL, QPCT, GLS | CTSB 2658/4885CTSK 2891/4885CTSS 2246/4885 |
| US-20140065095-A1 | NOVEL INHIBITORS | GLUL, QPCT, GLS | CTSB 2658/4885CTSK 2891/4885CTSS 2246/4885 |
| US-20080103137-A1 | Deazapurines and uses thereof | TPMT, TYMP, ENTPD5 | CTSB 2656/4885CTSK 3354/4885CTSS 3905/4885 |
| US-20040186127-A1 | Novel deazapurines and uses thereof | TPMT, ENTPD5, MTAP | CTSB 1818/4885CTSK 2500/4885CTSS 2563/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.